In a randomised, placebo‐controlled trial in women at high risk of OHSS, a second dose of kisspeptin‐54 (9.6 nmol/kg) 10 h following the first dose induced further LH secretion.83 Here, KISS1 is linked to ovarian hyperstimulation syndrome.